Literature DB >> 22973886

Targeting host factors to circumvent anti-malarial drug resistance.

Miguel Prudêncio1, Maria M Mota.   

Abstract

The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen's own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22973886     DOI: 10.2174/138161213804070276

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  18 in total

1.  Targeting liver stage malaria with metformin.

Authors:  Iset Medina Vera; Margarida T Grilo Ruivo; Leonardo F Lemos Rocha; Sofia Marques; Sangeeta N Bhatia; Maria M Mota; Liliana Mancio-Silva
Journal:  JCI Insight       Date:  2019-12-19

Review 2.  Opportunities for Host-targeted Therapies for Malaria.

Authors:  Elizabeth K K Glennon; Selasi Dankwa; Joseph D Smith; Alexis Kaushansky
Journal:  Trends Parasitol       Date:  2018-08-16

3.  Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites.

Authors:  Clare M Smith; Ante Jerkovic; Hervé Puy; Ingrid Winship; Jean-Charles Deybach; Laurent Gouya; Giel van Dooren; Christopher Dean Goodman; Angelika Sturm; Hana Manceau; Geoffrey Ian McFadden; Peter David; Odile Mercereau-Puijalon; Gaétan Burgio; Brendan J McMorran; Simon J Foote
Journal:  Blood       Date:  2014-11-20       Impact factor: 22.113

4.  Discovery of Druggable Host Factors Critical to Plasmodium Liver-Stage Infection.

Authors:  Rene Raphemot; Maria Toro-Moreno; Kuan-Yi Lu; Dora Posfai; Emily Rose Derbyshire
Journal:  Cell Chem Biol       Date:  2019-06-27       Impact factor: 8.116

Review 5.  Antiparasitic chemotherapy: from genomes to mechanisms.

Authors:  David Horn; Manoj T Duraisingh
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-09-11       Impact factor: 13.820

6.  Basigin is a druggable target for host-oriented antimalarial interventions.

Authors:  Zenon A Zenonos; Sara K Dummler; Nicole Müller-Sienerth; Jianzhu Chen; Peter R Preiser; Julian C Rayner; Gavin J Wright
Journal:  J Exp Med       Date:  2015-07-20       Impact factor: 14.307

7.  Treatment of erythrocytes with the 2-cys peroxiredoxin inhibitor, Conoidin A, prevents the growth of Plasmodium falciparum and enhances parasite sensitivity to chloroquine.

Authors:  Mariana Brizuela; Hong Ming Huang; Clare Smith; Gaetan Burgio; Simon J Foote; Brendan J McMorran
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

8.  Chemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA viruses.

Authors:  Marta J Gonzalez-Hernandez; Anupama Pal; Kofi E Gyan; Marie-Eve Charbonneau; Hollis D Showalter; Nicholas J Donato; Mary O'Riordan; Christiane E Wobus
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

9.  Asiatic acid influences parasitaemia reduction and ameliorates malaria anaemia in P. berghei infected Sprague-Dawley male rats.

Authors:  G A Mavondo; B N Mkhwananzi; M V Mabandla; C T Musabayane
Journal:  BMC Complement Altern Med       Date:  2016-09-13       Impact factor: 3.659

10.  Plasmodium parasite exploits host aquaporin-3 during liver stage malaria infection.

Authors:  Dora Posfai; Kayla Sylvester; Anupama Reddy; Jack G Ganley; Johannes Wirth; Quinlan E Cullen; Tushar Dave; Nobutaka Kato; Sandeep S Dave; Emily R Derbyshire
Journal:  PLoS Pathog       Date:  2018-05-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.